Cargando…
Intensity Modulated Radiotherapy (IMRT) + Carbon Ion Boost for Adenoid Cystic Carcinoma of the Minor Salivary Glands in the Oral Cavity
Background: Adenoid cystic carcinoma (ACC) are more common in the minor salivary glands (MiSGs) than the major salivary glands, and are characterized by slow tumor progression and frequently local recurrence. The main treatment option is surgery followed by combined radiotherapy. Methods: A retrospe...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6315550/ https://www.ncbi.nlm.nih.gov/pubmed/30518108 http://dx.doi.org/10.3390/cancers10120488 |
_version_ | 1783384321488322560 |
---|---|
author | Lang, Kristin Baur, Melissa Akbaba, Sati Held, Thomas Kargus, Steffen Bougatf, Nina Bernhardt, Denise Freier, Kolja Plinkert, Peter K. Rieken, Stefan Debus, Jürgen Adeberg, Sebastian |
author_facet | Lang, Kristin Baur, Melissa Akbaba, Sati Held, Thomas Kargus, Steffen Bougatf, Nina Bernhardt, Denise Freier, Kolja Plinkert, Peter K. Rieken, Stefan Debus, Jürgen Adeberg, Sebastian |
author_sort | Lang, Kristin |
collection | PubMed |
description | Background: Adenoid cystic carcinoma (ACC) are more common in the minor salivary glands (MiSGs) than the major salivary glands, and are characterized by slow tumor progression and frequently local recurrence. The main treatment option is surgery followed by combined radiotherapy. Methods: A retrospective analysis contained 67 patients with ACC of MiSGs in the oral cavity who underwent surgery followed by radiotherapy. The median cumulative IMRT dose was 50 Gy followed by 24 Gy for carbon ion (C12) boost. Median follow-up was 40 months. Results: Median 5-years overall survival (OS), progression-free survival (PFS) and local disease-free survival (LDFS) rates were 85.5%, 57.4% and 74.9%. Median time until progression was detected was 32 months (range: 2–205 months). Early grade ≥3 mucositis, dermatitis, and dysphagia were detected in 52.2%, 7.5% and 11.9% respectively. Besides common toxicities, two patients (3.0%) developed grade 3 toxicities with osteoradionecrosis of the jaw after 18 and 66 months. Higher-grade late toxicity (CTCAE grade 4) was not detected. No treatment-related death was detected. Conclusions: Our results demonstrate that postoperative combined radiotherapy with IMRT plus C12 boost seems to be a feasible and effective treatment method in ACC of MiSGs in the oral cavity, with good control and survival rates and adequate toxicity. |
format | Online Article Text |
id | pubmed-6315550 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-63155502019-01-09 Intensity Modulated Radiotherapy (IMRT) + Carbon Ion Boost for Adenoid Cystic Carcinoma of the Minor Salivary Glands in the Oral Cavity Lang, Kristin Baur, Melissa Akbaba, Sati Held, Thomas Kargus, Steffen Bougatf, Nina Bernhardt, Denise Freier, Kolja Plinkert, Peter K. Rieken, Stefan Debus, Jürgen Adeberg, Sebastian Cancers (Basel) Article Background: Adenoid cystic carcinoma (ACC) are more common in the minor salivary glands (MiSGs) than the major salivary glands, and are characterized by slow tumor progression and frequently local recurrence. The main treatment option is surgery followed by combined radiotherapy. Methods: A retrospective analysis contained 67 patients with ACC of MiSGs in the oral cavity who underwent surgery followed by radiotherapy. The median cumulative IMRT dose was 50 Gy followed by 24 Gy for carbon ion (C12) boost. Median follow-up was 40 months. Results: Median 5-years overall survival (OS), progression-free survival (PFS) and local disease-free survival (LDFS) rates were 85.5%, 57.4% and 74.9%. Median time until progression was detected was 32 months (range: 2–205 months). Early grade ≥3 mucositis, dermatitis, and dysphagia were detected in 52.2%, 7.5% and 11.9% respectively. Besides common toxicities, two patients (3.0%) developed grade 3 toxicities with osteoradionecrosis of the jaw after 18 and 66 months. Higher-grade late toxicity (CTCAE grade 4) was not detected. No treatment-related death was detected. Conclusions: Our results demonstrate that postoperative combined radiotherapy with IMRT plus C12 boost seems to be a feasible and effective treatment method in ACC of MiSGs in the oral cavity, with good control and survival rates and adequate toxicity. MDPI 2018-12-04 /pmc/articles/PMC6315550/ /pubmed/30518108 http://dx.doi.org/10.3390/cancers10120488 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Lang, Kristin Baur, Melissa Akbaba, Sati Held, Thomas Kargus, Steffen Bougatf, Nina Bernhardt, Denise Freier, Kolja Plinkert, Peter K. Rieken, Stefan Debus, Jürgen Adeberg, Sebastian Intensity Modulated Radiotherapy (IMRT) + Carbon Ion Boost for Adenoid Cystic Carcinoma of the Minor Salivary Glands in the Oral Cavity |
title | Intensity Modulated Radiotherapy (IMRT) + Carbon Ion Boost for Adenoid Cystic Carcinoma of the Minor Salivary Glands in the Oral Cavity |
title_full | Intensity Modulated Radiotherapy (IMRT) + Carbon Ion Boost for Adenoid Cystic Carcinoma of the Minor Salivary Glands in the Oral Cavity |
title_fullStr | Intensity Modulated Radiotherapy (IMRT) + Carbon Ion Boost for Adenoid Cystic Carcinoma of the Minor Salivary Glands in the Oral Cavity |
title_full_unstemmed | Intensity Modulated Radiotherapy (IMRT) + Carbon Ion Boost for Adenoid Cystic Carcinoma of the Minor Salivary Glands in the Oral Cavity |
title_short | Intensity Modulated Radiotherapy (IMRT) + Carbon Ion Boost for Adenoid Cystic Carcinoma of the Minor Salivary Glands in the Oral Cavity |
title_sort | intensity modulated radiotherapy (imrt) + carbon ion boost for adenoid cystic carcinoma of the minor salivary glands in the oral cavity |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6315550/ https://www.ncbi.nlm.nih.gov/pubmed/30518108 http://dx.doi.org/10.3390/cancers10120488 |
work_keys_str_mv | AT langkristin intensitymodulatedradiotherapyimrtcarbonionboostforadenoidcysticcarcinomaoftheminorsalivaryglandsintheoralcavity AT baurmelissa intensitymodulatedradiotherapyimrtcarbonionboostforadenoidcysticcarcinomaoftheminorsalivaryglandsintheoralcavity AT akbabasati intensitymodulatedradiotherapyimrtcarbonionboostforadenoidcysticcarcinomaoftheminorsalivaryglandsintheoralcavity AT heldthomas intensitymodulatedradiotherapyimrtcarbonionboostforadenoidcysticcarcinomaoftheminorsalivaryglandsintheoralcavity AT kargussteffen intensitymodulatedradiotherapyimrtcarbonionboostforadenoidcysticcarcinomaoftheminorsalivaryglandsintheoralcavity AT bougatfnina intensitymodulatedradiotherapyimrtcarbonionboostforadenoidcysticcarcinomaoftheminorsalivaryglandsintheoralcavity AT bernhardtdenise intensitymodulatedradiotherapyimrtcarbonionboostforadenoidcysticcarcinomaoftheminorsalivaryglandsintheoralcavity AT freierkolja intensitymodulatedradiotherapyimrtcarbonionboostforadenoidcysticcarcinomaoftheminorsalivaryglandsintheoralcavity AT plinkertpeterk intensitymodulatedradiotherapyimrtcarbonionboostforadenoidcysticcarcinomaoftheminorsalivaryglandsintheoralcavity AT riekenstefan intensitymodulatedradiotherapyimrtcarbonionboostforadenoidcysticcarcinomaoftheminorsalivaryglandsintheoralcavity AT debusjurgen intensitymodulatedradiotherapyimrtcarbonionboostforadenoidcysticcarcinomaoftheminorsalivaryglandsintheoralcavity AT adebergsebastian intensitymodulatedradiotherapyimrtcarbonionboostforadenoidcysticcarcinomaoftheminorsalivaryglandsintheoralcavity |